Abstract
Although the optimal sequential treatment (neoadjuvant therapy [NA] vs upfront surgery) for patients (pts) with cT1-2 cN0 HER2+ is unknown, previous studies suggest that NA is associated with lower rates of pN+ compared to those undergoing upfront surgery. Here, we evaluated the incidence of pathologic nodal disease in cT1-2 cN0 HER2+ pts treated with upfront surgery vs NA at 2 major academic hospitals in Spain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
